IVIM Technology is accelerating global sales of its proprietary intravital microscopy systems after securing multiple supply contracts this year, showcasing its technological competitiveness in overseas markets. The company aims to begin a period of full-scale earnings growth this year.
IVIM Technology said Thursday that it is expanding its overseas presence beyond the United States, Europe and Asia, with a focus on Southeast Asia. It has established a foothold in the region by signing new distributor agreements in Vietnam and Indonesia this year.
The company developed an intravital microscope that enables real-time observation of microenvironments and cell movements inside living organisms.
The technology can be used in drug development research to assess drug delivery efficiency and efficacy in animal models. In addition to selling microscopes, IVIM provides advanced research and analytical services essential to the preclinical stages of drug development.
Orders have been rising rapidly as the company's brand recognition grows both at home and abroad. In September, IVIM drew industry attention by supplying its microscopes to the National Institute of Environmental Health Sciences (NIEHS), under the U.S. National Institutes of Health (NIH), and Yale University.
The company said the deals demonstrated growing recognition of the reliability of its technology within the U.S. public health research ecosystem.
IVIM is seeking to improve its financial performance based on multiple supply contracts secured this year. Revenue for the first nine months reached 4.4 billion won, up 74.5 percent from the same period last year. Its cumulative operating loss narrowed to 2.8 billion won.
The company also added a new growth driver by launching a contract research organization (CRO) business in the second half of this year, leveraging its intravital microscopy solutions.
The service targets biotech companies and university laboratories that find it difficult to purchase the equipment themselves, providing outsourced validation of drug candidates and basic medical research.
IVIM said interest in its solutions has grown as global research into next-generation treatment modalities, including antibody-drug conjugates (ADCs) and gene therapies, has expanded. Its technology enables researchers to track and observe cell movements inside living organisms.
"Orders have recently increased as awareness of our intravital microscopes has grown in overseas markets, our customer base has expanded and our sales capabilities have strengthened," a company official said. "Our recent business with the NIH and Yale University has further validated our competitiveness in the global market."
The official added that IVIM is preparing to secure larger bulk orders from major clients, rather than relying solely on individual equipment sales, while continuing to expand its overseas distributor network.
"We plan to enter a period of full-scale earnings growth and will first work toward reaching break-even next year," the official said.
in THEBIO
